StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)

Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%

AbbVie revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

AbbVie's revenue for the twelve months ending Jun 30, 2026 was $64.39B, up 10.4% year over year. For fiscal 2025 it was $61.16B, up 8.6% from the year before. Over ten years it grew 10.3% a year on average. The highest annual figure on record is $61.16B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$61.16B+8.6%
FY2024Dec 31, 2024$56.33B+3.7%
FY2023Dec 31, 2023$54.32B-6.4%
FY2022Dec 31, 2022$58.05B+3.3%
FY2021Dec 31, 2021$56.20B+22.7%
FY2020Dec 31, 2020$45.80B+37.7%
FY2019Dec 31, 2019$33.27B+1.6%
FY2018Dec 31, 2018$32.75B+16.1%
FY2017Dec 31, 2017$28.22B+10.1%
FY2016Dec 31, 2016$25.64B+12.2%
FY2015Dec 31, 2015$22.86B+14.5%
FY2014Dec 31, 2014$19.96B+6.2%
FY2013Dec 31, 2013$18.79B+2.2%
FY2012Dec 31, 2012$18.38B+5.4%
FY2011Dec 31, 2011$17.44B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.99B+10.2%
Q1 FY2026Mar 31, 2026$15.00B+12.4%
Q4 FY2025Dec 31, 2025$16.62B+10.0%
Q3 FY2025Sep 30, 2025$15.78B+9.1%
Q2 FY2025Jun 30, 2025$15.42B+6.6%
Q1 FY2025Mar 31, 2025$13.34B+8.4%
Q4 FY2024Dec 31, 2024$15.10B+5.6%
Q3 FY2024Sep 30, 2024$14.46B+3.8%
Q2 FY2024Jun 30, 2024$14.46B+4.3%
Q1 FY2024Mar 31, 2024$12.31B+0.7%
Q4 FY2023Dec 31, 2023$14.30B-5.4%
Q3 FY2023Sep 30, 2023$13.93B-6.0%
Q2 FY2023Jun 30, 2023$13.87B-4.9%
Q1 FY2023Mar 31, 2023$12.23B-9.7%
Q4 FY2022Dec 31, 2022$15.12B+1.6%
Q3 FY2022Sep 30, 2022$14.81B+3.3%
Q2 FY2022Jun 30, 2022$14.58B+4.5%
Q1 FY2022Mar 31, 2022$13.54B+4.1%
Q4 FY2021Dec 31, 2021$14.89B+7.4%
Q3 FY2021Sep 30, 2021$14.34B+11.2%
Q2 FY2021Jun 30, 2021$13.96B+33.9%
Q1 FY2021Mar 31, 2021$13.01B+50.9%
Q4 FY2020Dec 31, 2020$13.86B+59.2%
Q3 FY2020Sep 30, 2020$12.90B+52.2%
Q2 FY2020Jun 30, 2020$10.43B+26.3%
Q1 FY2020Mar 31, 2020$8.62B+10.1%
Q4 FY2019Dec 31, 2019$8.70B+4.8%
Q3 FY2019Sep 30, 2019$8.48B+3.0%
Q2 FY2019Jun 30, 2019$8.26B-0.3%
Q1 FY2019Mar 31, 2019$7.83B-1.3%
Q4 FY2018Dec 31, 2018$8.31B+7.3%
Q3 FY2018Sep 30, 2018$8.24B+17.7%
Q2 FY2018Jun 30, 2018$8.28B+19.2%
Q1 FY2018Mar 31, 2018$7.93B+21.4%
Q4 FY2017Dec 31, 2017$7.74B+13.9%
Q3 FY2017Sep 30, 2017$7.00B+8.8%
Q2 FY2017Jun 30, 2017$6.94B–
Q1 FY2017Mar 31, 2017$6.54B–
Q4 FY2016Dec 31, 2016$6.80B–
Q3 FY2016Sep 30, 2016$6.43B–

More AbbVie figures

See a number that looks wrong?